Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rallybio
Biotech
Candid scores Nasdaq listing via reverse merger Rallybio
The deal will allow Candid to trade on the Nasdaq while dumping RallyBio’s own rare disease maternal-fetal medicine assets.
Will Maddox
Mar 2, 2026 11:45am
Rallybio shifts gears, cashing out of Recursion pact
Jul 8, 2025 8:59am
RallyBio cuts deeper, laying off 40% of workforce
May 8, 2025 9:00am
Rallybio drops lead program as phase 2 data disappoint
Apr 8, 2025 8:52am
Rallybio reins in preclinical, Monopar pivots to radiopharma
May 9, 2024 10:13am
J&J funds Rallybio in risk-busting rare pregnancy disease pact
Apr 10, 2024 4:00pm
